Abiopharma

🔍 Chawla Mandeep (Executive)

Company: CELESTICA INC (CLS)

Report Date: 2026-07-31

Detailed Transactions and Holdings:

• Sold 83 shares of Common Shares at $360.0 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 82,361.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 160 shares of Common Shares at $362.58 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 82,201.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 80 shares of Common Shares at $364.63 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 82,121.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 160 shares of Common Shares at $366.01 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,961.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 120 shares of Common Shares at $367.6 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,841.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 40 shares of Common Shares at $368.9 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,801.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 80 shares of Common Shares at $370.0 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,721.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 120 shares of Common Shares at $371.51 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,601.00 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 40 shares of Common Shares at $374.03 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: false | shares_owned_after: 81,561.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 13, 2026.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.38-$362.95, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.47-$364.80, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.77-$366.59, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.39-$368.02, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.92-$370.08, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $371.06-$372.01, inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.